In this episode, David Paul interviews Angela Lai, the founder and CEO of Betteromics. They discuss Angela’s background in the tech industry and her transition to the life sciences business. They explore the intersection of biology, chemistry, big data, and AI in the field of healthcare science. Angela explains how Betteromics serves as a regulated data lake for healthcare science data, providing a system of record and interoperability for clinical discovery. They also discuss the challenges and opportunities in the life science industry, the future of pharma and personalized medicine, and the importance of transparency and storytelling in the industry. Angela shares her insights as a founder and the personal growth she has experienced in building a startup. You can watch/listen to the podcast on YouTube, Spotify, and Apple.
Takeaways
- The life science industry is undergoing a transformation as biology, chemistry, big data, and AI converge.
- Betteromics serves as a regulated data lake for healthcare science data, providing a system of record and interoperability for clinical discovery.
- The life science industry faces challenges in data fragmentation, data governance, and the need for more efficient and predictable drug development.
- Specialty pharma medicines, personalized medicine, and biologics are the future of the industry.
- Founding a startup requires versatility, problem-solving skills, and a willingness to learn and adapt.
Chapters
02:08 Transition from Google to Grail to Betteromics
03:32 The Intersection of Biology, Chemistry, Big Data, and AI
06:06 Betteromics as a Regulated Data Lake for Healthcare Science
09:08 Challenges in the Life Science Industry
12:18 Positioning Betteromics in the Market
16:23 The Future of Pharma and Life Science
19:40 Technological Advances Enabling Betteromics
22:52 The Success Rate of Drugs and Therapies
28:14 The Opacity of the Life Science Industry
31:17 The Rise of Specialty Pharma Medicines
34:30 Lessons Learned as a Founder
37:49 Personal Growth and Privilege
